COVID-19, surprise!

Astonishingly, we have found that the same enzymes awry in ALS are also used by SARS-CoV-2 in multiplying in host cells, which opens up new potential therapies: we have alliances throughout the world for testing these. We are looking for support to move these therapies forward urgently.

Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic lateral sclerosis, or ALS, is a progressive nervous system disease where patients become progressively paralysed. We have shown with a big research consortium, massive changes in lipid metabolism which give new perspectives for a cure, and have orphan drug designation for a generic drug, ambroxol, which will start clinical trials soon. Our 8 year experience has been very innovative and we have multiple opportunities. Thus our business plans are very flexible, but we welcome sponsors who can interact positively with us, taking options on success – which could be revolutionary, increasing our little company exponentially.

Consultancy and Research:
Creation of value by research

Resolution of apparently intractable problems by:

  • Lateral thinking
  • Experimentation
  • Research consortia

Avoid previous mistakes by experience

What we do

We address human “impossible” diseases, pharma, biotech, society and ecology issues

We organise research consortia, symposia, the means to answer key problems

We instill hope and pragmatic solutions

We do research!

What we did

Seven years of the company

  • Established formally as a young innovative company (JEI), eligible for research credits (CIR), with multiple research grants
  • Employed scientists directly in research labs, in multiple collaborations
  • From setting up the company in 2013, we have been involved with 60 Pubmed publications and been listed every year in the Clarivate list of most cited scientists (all disciplines, <150 classed in France)
  • Discovered a new way in for motor neurone disease and identified a patented phase2-ready compound, which has orphan drug designation for ALS, and collaborations in Parkinson’s Disease. This breakthrough has been obtained by a multiple collaborations (see research pages). We are now working on partnership and development.
  • Made a remarkable breakthrough, realising in February 2020 that the enzymes we showed were awry in ALS, are targets for SARS-CoV-2, and can be modified with therapeutic benefit. We are working on clinical trials and setting up major collaborations – we have a major opportunity and are looking to extend our partnerships.
  • Worked on the human limits in performance and ageing showing ageing decline is reflected in a precise single exponential, related toVO2max, with remarkable precision.
  • As Secretary-General of International Union of Pharmacology, IUPHAR, a critical role in world health-care and research. 

Thus we now have the possibility of bringing major therapeutic benefit in ALS and COVID-19

Successful cooperation needs goals, organisation, follow-up and to be win-win. Validation of concepts is via
experimentation, and experimental design is critical. That is one of our strengths.

.sciencex_footer { font-size: 10px; }